Johannes Jacob Pieter Kastelein is the Chief Scientific Officer (CSO) and Director at NewAmsterdam Pharma Company N.V. (NAMS), a biopharmaceutical company focused on cardiovascular diseases.( He has been actively involved in recent insider trading activities, including selling 100,000 shares worth approximately $2.47 million, 6,000 shares at $33.25 each on January 5, 2026, and other transactions totaling over 106,000 shares sold across multiple filings.(

Kastelein, aged 71 as of recent records, serves in a dual executive and board role at the Naarden, Netherlands-based firm, with his professional address listed at the company's headquarters.( SEC filings confirm his reporting under CIK 0002000389, documenting sales from 2025 into 2026, though detailed prior career highlights and education are not specified in available sources.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.